Mometasone furoate: Efficacy and safety in moderate asthma compared with beclomethasone dipropionate

Robert A. Nathan, Anjuli S. Nayak, David F. Graft, Michael Lawrence, Frank J. Picone, Tahir Ahmed, James Wolfe, Mark L. Vanderwalker, Keith B. Nolop, Judy E. Harrison

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background: Mometasone furoate (MF) is a new inhaled glucocorticoid administered by dry powder inhaler (DPI). Objective: MF-DPI was evaluated for safety and efficacy and compared with placebo DPI and beclomethasone dipropionate (BDP) administered by metered dose inhaler (MDI) in the treatment of patients with moderate persistent asthma. Methods: Eligible patients (n = 227), 13 to 75 years of age, maintained on inhaled glucocorticoids before entering the trial, were randomized to receive: MF-DPI, 100 μg, twice daily, MF-DPI, 200 μg, twice daily, BDP MDI, 168 μg, twice daily, or placebo in a 12-week, multicenter, double-blind study. Results: At endpoint, FEV 1 (primary efficacy variable) significantly improved for all three active treatments compared with placebo (P < 0.01, all comparisons). The response to MF-DPI, 200 μg, twice daily treatment was approximately twice as large as the response to MF-DPI, 100 μg, twice daily or BDP MDI treatment, although the differences between these groups did not reach statistical significance. Secondary efficacy variables including PEFR, asthma symptoms, nocturnal awakenings, and albuterol use showed similar trends. The MF-DPI, 100 μg, twice daily and BDP MDI, 168 μg, twice daily treatment groups produced comparable results for all efficacy variables. Conclusions: MF-DPI, 100 μg and 200 μg, twice daily were well-tolerated and significantly improved lung function and symptom control in the treatment of patients with moderate persistent asthma. In this study, MF-DPI, 200 μg, twice daily seemed to be the most effective dosage.

Original languageEnglish
Pages (from-to)203-210
Number of pages8
JournalAnnals of Allergy, Asthma and Immunology
Volume86
Issue number2
StatePublished - Mar 3 2001
Externally publishedYes

Fingerprint

Mometasone Furoate
Dry Powder Inhalers
Beclomethasone
Asthma
Safety
Metered Dose Inhalers
Placebos
Glucocorticoids
Therapeutics
Peak Expiratory Flow Rate

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

Nathan, R. A., Nayak, A. S., Graft, D. F., Lawrence, M., Picone, F. J., Ahmed, T., ... Harrison, J. E. (2001). Mometasone furoate: Efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Annals of Allergy, Asthma and Immunology, 86(2), 203-210.

Mometasone furoate : Efficacy and safety in moderate asthma compared with beclomethasone dipropionate. / Nathan, Robert A.; Nayak, Anjuli S.; Graft, David F.; Lawrence, Michael; Picone, Frank J.; Ahmed, Tahir; Wolfe, James; Vanderwalker, Mark L.; Nolop, Keith B.; Harrison, Judy E.

In: Annals of Allergy, Asthma and Immunology, Vol. 86, No. 2, 03.03.2001, p. 203-210.

Research output: Contribution to journalArticle

Nathan, RA, Nayak, AS, Graft, DF, Lawrence, M, Picone, FJ, Ahmed, T, Wolfe, J, Vanderwalker, ML, Nolop, KB & Harrison, JE 2001, 'Mometasone furoate: Efficacy and safety in moderate asthma compared with beclomethasone dipropionate', Annals of Allergy, Asthma and Immunology, vol. 86, no. 2, pp. 203-210.
Nathan RA, Nayak AS, Graft DF, Lawrence M, Picone FJ, Ahmed T et al. Mometasone furoate: Efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Annals of Allergy, Asthma and Immunology. 2001 Mar 3;86(2):203-210.
Nathan, Robert A. ; Nayak, Anjuli S. ; Graft, David F. ; Lawrence, Michael ; Picone, Frank J. ; Ahmed, Tahir ; Wolfe, James ; Vanderwalker, Mark L. ; Nolop, Keith B. ; Harrison, Judy E. / Mometasone furoate : Efficacy and safety in moderate asthma compared with beclomethasone dipropionate. In: Annals of Allergy, Asthma and Immunology. 2001 ; Vol. 86, No. 2. pp. 203-210.
@article{e253609e39a04164b4af92aee108a85e,
title = "Mometasone furoate: Efficacy and safety in moderate asthma compared with beclomethasone dipropionate",
abstract = "Background: Mometasone furoate (MF) is a new inhaled glucocorticoid administered by dry powder inhaler (DPI). Objective: MF-DPI was evaluated for safety and efficacy and compared with placebo DPI and beclomethasone dipropionate (BDP) administered by metered dose inhaler (MDI) in the treatment of patients with moderate persistent asthma. Methods: Eligible patients (n = 227), 13 to 75 years of age, maintained on inhaled glucocorticoids before entering the trial, were randomized to receive: MF-DPI, 100 μg, twice daily, MF-DPI, 200 μg, twice daily, BDP MDI, 168 μg, twice daily, or placebo in a 12-week, multicenter, double-blind study. Results: At endpoint, FEV 1 (primary efficacy variable) significantly improved for all three active treatments compared with placebo (P < 0.01, all comparisons). The response to MF-DPI, 200 μg, twice daily treatment was approximately twice as large as the response to MF-DPI, 100 μg, twice daily or BDP MDI treatment, although the differences between these groups did not reach statistical significance. Secondary efficacy variables including PEFR, asthma symptoms, nocturnal awakenings, and albuterol use showed similar trends. The MF-DPI, 100 μg, twice daily and BDP MDI, 168 μg, twice daily treatment groups produced comparable results for all efficacy variables. Conclusions: MF-DPI, 100 μg and 200 μg, twice daily were well-tolerated and significantly improved lung function and symptom control in the treatment of patients with moderate persistent asthma. In this study, MF-DPI, 200 μg, twice daily seemed to be the most effective dosage.",
author = "Nathan, {Robert A.} and Nayak, {Anjuli S.} and Graft, {David F.} and Michael Lawrence and Picone, {Frank J.} and Tahir Ahmed and James Wolfe and Vanderwalker, {Mark L.} and Nolop, {Keith B.} and Harrison, {Judy E.}",
year = "2001",
month = "3",
day = "3",
language = "English",
volume = "86",
pages = "203--210",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "2",

}

TY - JOUR

T1 - Mometasone furoate

T2 - Efficacy and safety in moderate asthma compared with beclomethasone dipropionate

AU - Nathan, Robert A.

AU - Nayak, Anjuli S.

AU - Graft, David F.

AU - Lawrence, Michael

AU - Picone, Frank J.

AU - Ahmed, Tahir

AU - Wolfe, James

AU - Vanderwalker, Mark L.

AU - Nolop, Keith B.

AU - Harrison, Judy E.

PY - 2001/3/3

Y1 - 2001/3/3

N2 - Background: Mometasone furoate (MF) is a new inhaled glucocorticoid administered by dry powder inhaler (DPI). Objective: MF-DPI was evaluated for safety and efficacy and compared with placebo DPI and beclomethasone dipropionate (BDP) administered by metered dose inhaler (MDI) in the treatment of patients with moderate persistent asthma. Methods: Eligible patients (n = 227), 13 to 75 years of age, maintained on inhaled glucocorticoids before entering the trial, were randomized to receive: MF-DPI, 100 μg, twice daily, MF-DPI, 200 μg, twice daily, BDP MDI, 168 μg, twice daily, or placebo in a 12-week, multicenter, double-blind study. Results: At endpoint, FEV 1 (primary efficacy variable) significantly improved for all three active treatments compared with placebo (P < 0.01, all comparisons). The response to MF-DPI, 200 μg, twice daily treatment was approximately twice as large as the response to MF-DPI, 100 μg, twice daily or BDP MDI treatment, although the differences between these groups did not reach statistical significance. Secondary efficacy variables including PEFR, asthma symptoms, nocturnal awakenings, and albuterol use showed similar trends. The MF-DPI, 100 μg, twice daily and BDP MDI, 168 μg, twice daily treatment groups produced comparable results for all efficacy variables. Conclusions: MF-DPI, 100 μg and 200 μg, twice daily were well-tolerated and significantly improved lung function and symptom control in the treatment of patients with moderate persistent asthma. In this study, MF-DPI, 200 μg, twice daily seemed to be the most effective dosage.

AB - Background: Mometasone furoate (MF) is a new inhaled glucocorticoid administered by dry powder inhaler (DPI). Objective: MF-DPI was evaluated for safety and efficacy and compared with placebo DPI and beclomethasone dipropionate (BDP) administered by metered dose inhaler (MDI) in the treatment of patients with moderate persistent asthma. Methods: Eligible patients (n = 227), 13 to 75 years of age, maintained on inhaled glucocorticoids before entering the trial, were randomized to receive: MF-DPI, 100 μg, twice daily, MF-DPI, 200 μg, twice daily, BDP MDI, 168 μg, twice daily, or placebo in a 12-week, multicenter, double-blind study. Results: At endpoint, FEV 1 (primary efficacy variable) significantly improved for all three active treatments compared with placebo (P < 0.01, all comparisons). The response to MF-DPI, 200 μg, twice daily treatment was approximately twice as large as the response to MF-DPI, 100 μg, twice daily or BDP MDI treatment, although the differences between these groups did not reach statistical significance. Secondary efficacy variables including PEFR, asthma symptoms, nocturnal awakenings, and albuterol use showed similar trends. The MF-DPI, 100 μg, twice daily and BDP MDI, 168 μg, twice daily treatment groups produced comparable results for all efficacy variables. Conclusions: MF-DPI, 100 μg and 200 μg, twice daily were well-tolerated and significantly improved lung function and symptom control in the treatment of patients with moderate persistent asthma. In this study, MF-DPI, 200 μg, twice daily seemed to be the most effective dosage.

UR - http://www.scopus.com/inward/record.url?scp=0035117821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035117821&partnerID=8YFLogxK

M3 - Article

C2 - 11258691

AN - SCOPUS:0035117821

VL - 86

SP - 203

EP - 210

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 2

ER -